THE EFFICIENCY OF 48-WEEK TREATMENT WITH LOPINAVIR/RITONAVIR IN COMBINATION WITH LAMIVUDIN IN HIV-1-INFECTED PATIENTS IN THE ROUTINE CLINICAL SETTINGS OF THE RUSSIAN FEDERATION: RESULTS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY (THE SIMPLE STUDY)
- Authors: Orlova-Morozova E.A.1, Plotnikova Y.K.2, Pokrovskaya A.V.3,4, Radzikhovskaya M.V.5, Sizova N.V.6, Nagimova F.I.7, Mikhaylov S.P.8, Wegzyn C.M.9, Dorr P.K.9, Potapov A.V.10, Kruglova A.I.10
-
Affiliations:
- Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Irkutsk Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Peoples' Friendship University of Russia
- Chelyabinsk Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Saint Petersburg Center for Prevention and Control of AIDS and Communicable Diseases
- Republican Center for Prevention and Control of AIDS and Communicable Diseases, Ministry of Health of the Republic of Tatarstan
- Orenburg Regional Clinical Infectious Diseases Hospital
- AbbVie
- AbbVie FFC
- Issue: No 2 (2018)
- Pages: 56-64
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/322191
- DOI: https://doi.org/10.18565/epidem.2018.2.56-64
- ID: 322191
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Elena A. Orlova-Morozova
Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: orlovamorozova@gmail.com
Cand. Med. Sсi., Head, Outpatient Department Shchepkin St., 61/2, Build. 8, Moscowl29110, Russia
Yulia K. Plotnikova
Irkutsk Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: plotl8@yandex.ru
Cand. Med. Sсi., Head Irkutsk, Russia
Anastasia V. Pokrovskaya
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Peoples' Friendship University of Russia
Email: pokrovskaya_av@mail.ru
Cand. Med. Sсi., Senior Researcher, Central Research Institute of Epidemiology Moscow, Russia
Margarita V. Radzikhovskaya
Chelyabinsk Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: rita-rad@mail.ru
Cand. Med. Sсi., Principal Physician Chelyabinsk, Russia
Natalia V. Sizova
Saint Petersburg Center for Prevention and Control of AIDS and Communicable Diseases
Email: natalia_v_sizova@mail.ru
MD, Deputy Principal Physician Saint-Petersburg, Russia
Firaya I. Nagimova
Republican Center for Prevention and Control of AIDS and Communicable Diseases, Ministry of Health of the Republic of Tatarstan
Email: nagimova@list.ru
Cand. Med. Sсi., Deputy Principal Physician Kazan, Russia
Sergey P. Mikhaylov
Orenburg Regional Clinical Infectious Diseases Hospital
Email: serpemikh@yandex.ru
Cand. Med. Sсi., Deputy Principal Phsicians Orenburg, Russia
Colleen M. Wegzyn
AbbVie
Email: colleen.wegzyn@abbvie.com
Virology Therapeutic Area Lead Chicago, USA
Patrick K. Dorr
AbbVie
Email: patrick.dorr@abbvie.com
Medical Director Maidenhead, UK
Andrey V. Potapov
AbbVie FFC
Email: andrey.potapov@abbvie.com
Cand. Med. Sсi., Senior Clinical Project Manager Moscow Russia
Anna I. Kruglova
AbbVie FFC
Email: anna.kruglova@abbvie.com
Cand. Biol. Sсi., Senior Medical Adviser Moscow, Russia
References
- ВИЧ-инфекция у взрослых. Клинические рекомендации КР79. М., 2017. https://medi.ru/klinicheskie-rekomendatsii/vich-irrfektsiya-u-vzroslykh_ 14332/
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова В.В., Нарсия P.C., Хохлова О.Н., Покровская А.В., Ефремова О.С., Коннов В.В., КуимоваУА, Попова АА., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол. Эпидемиол. инфекц. болезни. Актуал. вопр. 2017; (6, приложение): 14.
- D’Andrea G., BrisdeUi F., Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol. 2008; 3(1): 20-37.
- Hemández В., Moreno S., Pérez-Elias M.J., Casado J.L., Dronda F., Moreno A. et al. Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients. J. Acquir. Immune Defic Syndr. 2006; 43(5): 556-9.
- Bedimo R., Rosenblatt L., Myeis J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. HIV Clin. Trials. 2016; 17(6): 246-66.
- Avarez A., Orden S., Andujar I., Collado-Diaz V., Niinez-Delgado S., Galindo M.J. et al. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS. 2017; 31(13): 1781-95.
- Cahn P., Andrade-Vfflanueva J., Aribas J. R., Gatell J. M., Lama J.R., Norton M. et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, noninferiority GARDEL trial. Lancet Infect. Dis. 2014; 14: 572-80.
- Arribas J.R., Girard P.M., Landman R., Pich J., Mallolas J., Martinez-Rebollar M. et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t) ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect. Dis. 2015; 15(7): 785-92.
- Murphy R.L., Da Silva B.A., Hicks C.B., Eron J.J., Gulick R.M., Thompson MA. et al. Seven-year efficacy of a lopinavir/ ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin. Trials. 2008; 9(1): 1-10.
Supplementary files
![](/img/style/loading.gif)